Women with advanced or recurring ovarian, peritoneal, or fallopian tube cancer may be eligible to enroll in a new clinical trial offered through Sarasota Memorial’s Kolschowsky Research and Education Institute.
The study, led locally by gynecologic oncology surgeons Beverly Long, MD, and Toni Kilts, DO, with Sarasota Memorial’s First Physicians Group and Brian D. Jellison Cancer Institute, is testing different dosing schedules of the investigational drug Mirvetuximab Soravtansine. The drug targets folate receptor-alpha (FRα), a protein found in high levels on many ovarian, fallopian tube, and primary peritoneal cancer cells.
By focusing on FRα, Mirvetuximab Soravtansine is designed to identify and attack cancer cells more precisely, with reduced impact on nearby healthy cells. The trial aims to measure clinical benefit while exploring dosing regimens that may offer more convenience to patients…